Quest Diagnostics profit falls 12%, but beats estimate
Quest Diagnostics Inc. (DGX) said Tuesday its third-quarter profit dropped by 12.2% to $225 million, or $1.96 a share, from $256 million, or $2.17 a share, in the year-ago quarter. Adjusted third-quarter profit fell to $2.22 a share from $2.36 a share, and beat the FactSet consensus estimate of $2.19 a share. Revenue at the medical products company dropped by 7.7% to $2.295 billion, ahead of the analyst estimate of $2.269 billion. Looking ahead, Quest Diagnostics said it expects adjusted 2023 earnings of $8.65 to $8.75 a share, against the analyst estimate of $8.71 share, with revenue of $9.19 billion to $9.24 billion, compared to the Wall Street expectation of $9.18 billion. Quest Diagnostics stock was not trading in the pre-market. The stock is down about 22% in 2023, compared to a 9.8% gain by the S&P 500 .
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-24-23 0703ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States